{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-048151","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-07-14T20:05:25+00:00","discovered_at":"2026-07-14T20:06:00.581698+00:00","generated_at":"2026-07-14T20:06:30.061896+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Crescent Biopharma reports preliminary Q2 2026 cash of $171.6M","bullets":["Cash and cash equivalents estimated at $171.6M as of June 30, 2026.","Preliminary, unaudited data subject to completion of financial closing procedures.","PricewaterhouseCoopers has not audited, reviewed, or compiled the estimate."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-048151","json":"https://secwatch.observer/filing/0001628280-26-048151.json","markdown":"https://secwatch.observer/filing/0001628280-26-048151.md","text":"https://secwatch.observer/filing/0001628280-26-048151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026048151/0001628280-26-048151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026048151/cbio-20260714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T20:06:30.061896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}